COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · IEX Real-Time Price · USD
7.86
-0.24 (-2.96%)
At close: Apr 25, 2024, 4:00 PM
8.24
+0.38 (4.83%)
Pre-market: Apr 26, 2024, 4:51 AM EDT
COMPASS Pathways Market Cap
COMPASS Pathways has a market cap or net worth of $486.88 million as of April 26, 2024. Its market cap has increased by 16.42% in one year.
Market Cap
486.88M
Enterprise Value
299.29M
1-Year Change
16.42%
Ranking
Category
Stock Price
$7.86
Market Cap Chart
Since the IPO on September 18, 2020, COMPASS Pathways's market cap has decreased from $568.58M to $486.88M, a decrease of -14.37%. That is a compound annual growth rate of -4.21%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 25, 2024 | 504.80M | -2.96% |
| Apr 24, 2024 | 520.20M | -1.83% |
| Apr 23, 2024 | 529.90M | -1.30% |
| Apr 22, 2024 | 536.90M | -0.24% |
| Apr 19, 2024 | 538.20M | -0.48% |
| Apr 18, 2024 | 540.80M | -1.30% |
| Apr 17, 2024 | 547.90M | -2.84% |
| Apr 16, 2024 | 563.90M | 5.52% |
| Apr 15, 2024 | 534.40M | -3.92% |
| Apr 12, 2024 | 556.20M | -5.66% |
| Apr 11, 2024 | 589.60M | 0.10% |
| Apr 10, 2024 | 589.00M | -4.18% |
| Apr 9, 2024 | 614.70M | -1.74% |
| Apr 8, 2024 | 625.60M | 2.52% |
| Apr 5, 2024 | 610.20M | -3.05% |
| Apr 4, 2024 | 629.40M | 1.03% |
| Apr 3, 2024 | 623.00M | 2.65% |
| Apr 2, 2024 | 606.90M | -2.38% |
| Apr 1, 2024 | 621.70M | 16.34% |
| Mar 28, 2024 | 534.40M | -12.42% |
| Mar 27, 2024 | 610.20M | 2.04% |
| Mar 26, 2024 | 598.00M | 1.53% |
| Mar 25, 2024 | 589.00M | 2.12% |
| Mar 22, 2024 | 576.80M | -5.47% |
| Mar 21, 2024 | 610.20M | -2.85% |
View and export this data all the way back to 2020.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly | 708.20B |
| Novo Nordisk | 557.80B |
| UnitedHealth Group | 447.85B |
| Johnson & Johnson | 361.32B |
| Merck & Co. | 321.37B |
| AbbVie | 299.16B |
| AstraZeneca | 219.82B |
| Thermo Fisher | 219.16B |